Literature DB >> 23459475

Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in Mallard ducks.

Jenna E Achenbach1, Richard A Bowen.   

Abstract

Oseltamivir carboxylate (OC) has been detected in environmental waters at various levels during recent influenza seasons in humans, reflecting levels of usage and stability of this drug. In consideration of the role of waterfowl as hosts for influenza viruses that may contribute to human infections, we evaluated the effect of consumption of low doses of OC on development of oseltamivir-resistant influenza virus mutants in mallard ducks (Anas platyrhynchos) infected with two different low-pathogenic (LP) H5N2 avian influenza viruses (AIV). We detected development of virus variants carrying a known molecular marker of oseltamivir resistance (neuraminidase E119V) in 4 out of 6 mallards infected with A/Mallard/Minnesota/182742/1998 (H5N2) and exposed to 1,000 ng/liter OC. The mutation first appeared as a minor population on days 5 to 6 and was the dominant genotype on days 6 to 8. Oseltamivir-resistant mutations were not detected in virus from ducks not exposed to the drug or in ducks infected with a second strain of virus and similarly exposed to OC. Virus isolates carrying the E119V mutation displayed in vitro replication kinetics similar to those of the wild-type virus, but in vivo, the E119V virus rapidly reverted back to wild type in the absence of OC, and only the wild-type parental strain was transmitted to contact ducks. These results indicate that consumption by wild waterfowl of OC in drinking water may promote selection of the E119V resistance mutation in some strains of H5N2 AIV that could contribute to viruses infecting human populations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459475      PMCID: PMC3632944          DOI: 10.1128/AAC.02126-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

Review 1.  Functional balance between haemagglutinin and neuraminidase in influenza virus infections.

Authors:  Ralf Wagner; Mikhail Matrosovich; Hans-Dieter Klenk
Journal:  Rev Med Virol       Date:  2002 May-Jun       Impact factor: 6.989

2.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods.

Authors:  Koichiro Tamura; Daniel Peterson; Nicholas Peterson; Glen Stecher; Masatoshi Nei; Sudhir Kumar
Journal:  Mol Biol Evol       Date:  2011-05-04       Impact factor: 16.240

Review 3.  Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

Authors:  G He; J Massarella; P Ward
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

4.  Oral oseltamivir treatment of influenza in children.

Authors:  R J Whitley; F G Hayden; K S Reisinger; N Young; R Dutkowski; D Ipe; R G Mills; P Ward
Journal:  Pediatr Infect Dis J       Date:  2001-02       Impact factor: 2.129

5.  Universal primer set for the full-length amplification of all influenza A viruses.

Authors:  E Hoffmann; J Stech; Y Guan; R G Webster; D R Perez
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

6.  Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus.

Authors:  L J Mitnaul; M N Matrosovich; M R Castrucci; A B Tuzikov; N V Bovin; D Kobasa; Y Kawaoka
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

7.  Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir.

Authors:  L V Gubareva; L Kaiser; M N Matrosovich; Y Soo-Hoo; F G Hayden
Journal:  J Infect Dis       Date:  2001-01-11       Impact factor: 5.226

8.  The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

Authors:  J A L Ives; J A Carr; D B Mendel; C Y Tai; R Lambkin; L Kelly; J S Oxford; F G Hayden; N A Roberts
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

9.  Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets.

Authors:  M L Herlocher; J Carr; J Ives; S Elias; R Truscon; N Roberts; A S Monto
Journal:  Antiviral Res       Date:  2002-05       Impact factor: 5.970

10.  Characterization of influenza hemagglutinin interactions with receptor by NMR.

Authors:  Christopher McCullough; Minxiu Wang; Lijun Rong; Michael Caffrey
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

View more
  9 in total

1.  Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards.

Authors:  Anna Gillman; Shaman Muradrasoli; Hanna Söderström; Fredrik Holmberg; Neus Latorre-Margalef; Conny Tolf; Jonas Waldenström; Gunnar Gunnarsson; Björn Olsen; Josef D Järhult
Journal:  Appl Environ Microbiol       Date:  2015-01-23       Impact factor: 4.792

2.  2,5-Diketopiperazine Derivatives as Potential Anti-Influenza (H5N2) Agents: Synthesis, Biological Evaluation, and Molecular Docking Study.

Authors:  Chanakan Winyakul; Weerachai Phutdhawong; Poomipat Tamdee; Jitnapa Sirirak; Thongchai Taechowisan; Waya S Phutdhawong
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

3.  Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan.

Authors:  Takashi Azuma; Hirotaka Ishiuchi; Tomomi Inoyama; Yusuke Teranishi; Misato Yamaoka; Takaji Sato; Naoyuki Yamashita; Hiroaki Tanaka; Yoshiki Mino
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

4.  Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water.

Authors:  Anna Gillman; Marie Nykvist; Shaman Muradrasoli; Hanna Söderström; Michelle Wille; Annika Daggfeldt; Caroline Bröjer; Jonas Waldenström; Björn Olsen; Josef D Järhult
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

5.  Intra- and inter-pandemic variations of antiviral, antibiotics and decongestants in wastewater treatment plants and receiving rivers.

Authors:  Andrew C Singer; Josef D Järhult; Roman Grabic; Ghazanfar A Khan; Richard H Lindberg; Ganna Fedorova; Jerker Fick; Michael J Bowes; Björn Olsen; Hanna Söderström
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

Review 6.  Risk of resistant avian influenza A virus in wild waterfowl as a result of environmental release of oseltamivir.

Authors:  Anna Gillman
Journal:  Infect Ecol Epidemiol       Date:  2016-10-11

7.  Characterization of Novel Reassortant Influenza A (H5N2) Viruses Isolated from Poultry in Eastern China, 2015.

Authors:  Haibo Wu; Rufeng Lu; Xiuming Peng; Xiaorong Peng; Linfang Cheng; Fumin Liu; Nanping Wu
Journal:  Front Microbiol       Date:  2017-04-25       Impact factor: 5.640

Review 8.  Environmental resistance development to influenza antivirals: a case exemplifying the need for a multidisciplinary One Health approach including physicians.

Authors:  Josef D Järhult
Journal:  Acta Vet Scand       Date:  2018-01-25       Impact factor: 1.695

9.  Functional neuraminidase inhibitor resistance motifs in avian influenza A(H5Nx) viruses.

Authors:  Dagmara Bialy; Holly Shelton
Journal:  Antiviral Res       Date:  2020-08-01       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.